The American Journal of Managed Care14d
FDA Approves Companion Diagnostic for Tepotinib in MET Exon 14 mNSCLC
FoundationOne Liquid CDx is now FDA-approved to identify mNSCLC patients with MET exon 14 skipping alterations for tepotinib ...
特泊替尼（Tepotinib）副作用及注意事项
盐酸替波替尼是一种低分子化合物，对间质上皮转化因子（MET）具有抑制作用，是受体酪氨酸激酶。 盐酸替波替尼抑制MET的磷酸化，通过抑制下游信号转导，被认为表现出肿瘤生长抑制作用。
Targeted Oncology12d
FDA OKs FoundationOne Liquid CDx for Tepotinib in METex14-Skipping NSCLC
The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung ...
pharmaphorum3y
Merck's targeted lung cancer drug tepotinib wins early access in UK
The Medicines and Healthcare product Regulatory Agency (MHRA) has issued a positive opinion on tepotinib as a treatment for adult NSCLC patient whose tumours have METex14 skipping alterations ...
FDA 批准 FoundationOne Liquid CDx 用于治疗 METex14 跳跃型 NSCLC 患者
FDA 已批准 FoundationOne Liquid CDx 作为伴随诊断试剂，用于识别患有MET外显子 14 跳跃变异的转移性 NSCLC 患者。此项批准将帮助临床医生识别可能受益于特泊替尼 (Tepmetko) ...